[Future trends in anticancer chemotherapy].
Kudoh
Shinzoh
S
Department of Internal Medicine, Graduate School of Medicine, Osaka City University.
Yamauchi
Setsuko
S
D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D015195:Drug Design; D004358:Drug Therapy / Q000639:trends*; D015507:Drugs, Investigational; D016228:Endothelial Growth Factors / Q000276:immunology; D005544:Forecasting; D000077156:Gefitinib; D006801:Humans; D036341:Intercellular Signaling Peptides and Proteins / Q000276:immunology; D008175:Lung Neoplasms / Q000188:drug therapy*; D008222:Lymphokines / Q000276:immunology; D011799:Quinazolines; D011994:Recombinant Proteins; D000068878:Trastuzumab; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D015507:Drugs, Investigational; D016228:Endothelial Growth Factors; D036341:Intercellular Signaling Peptides and Proteins; D008222:Lymphokines; D011799:Quinazolines; D011994:Recombinant Proteins; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors; D000068878:Trastuzumab; D000077156:Gefitinib